Dr. Wehbe stands at the forefront of biotechnology innovation as co-founder of two revolutionary drug delivery platforms and former Co-Lead of Extrahepatic Targeting at Mirai Bio, where he conceived and developed groundbreaking technologies for targeted therapeutic delivery. His scientific leadership encompasses the complete product development lifecycle, from bench-scale research through large-animal studies and technology transfer to GMP manufacturing. His expertise in lipid nanoparticle (LNP) design and AI/ML integration has positioned him as a recognized authority in next-generation therapeutic platforms.

His impressive academic and research credentials include a Ph.D. in Pharmaceutical Sciences from the University of British Columbia, postdoctoral research at Vanderbilt University, and co-invention of the MetaplexTM copper-drug complexation technology, resulting in multiple patents and the founding of Cuprous Pharmaceuticals. With over 30 peer-reviewed publications and successful partnerships with venture groups, pharma collaborators, and industry leaders like AstraZeneca, Dr. Wehbe's mentorship provides unparalleled insights into biotech entrepreneurship, scientific innovation, and the intersection of cutting-edge research with commercial success, making him an invaluable guide for aspiring biotech leaders and scientific entrepreneurs.